News

The Zydus-Prolong agreement seeks to increase productivity in the drug development of this next generation therapeutic protein by leveraging the combined strengths of both companies. Under the terms

Twenty-five patients were treated with the combination of both substances. Patients have received once weekly infusions of WX-UK1 for three weeks at various fixed doses and daily capecitabine

The Phase II trial is designed as a randomized, double-blind, placebo- controlled, intent-to-treat, multi-center study to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine

As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma

Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons. Jack

TransTech made an undisclosed one-time payment to Novo Nordisk for acquisition of the programs. Adnan Mjalli, TransTech’s founder, chairman and CEO, said: “We are extremely pleased to have

The study will evaluate OncoGel administered in combination with pre-operative chemoradiotherapy versus pre-operative chemoradiotherapy alone in 124 patients. The primary endpoint of the study is a blinded assessment

The primary objective of the multi-center clinical trial is to assess the overall response rate to the combination of bavituximab with carboplatin and paclitaxel, chemotherapy drugs commonly used

The lawsuit was filed in the US District Court of Florida, Jacksonville Division, alleging violations of state consumer protection statutes, breach of warranty, and unjust enrichment. The lawsuit